THIS ARTICLE IS MORE THAN FIVE YEARS OLD
This article is more than five years old. Autism research - and science in general - is constantly evolving, so older articles may contain information or theories that have been reevaluated since their original publication date.
Researchers have used protein and drug interaction networks to identify drugs approved for one disorder that may be useful for treating another, they reported 18 January in Bioinformation1.
Using this method, the researchers suggest that four drugs approved to treat high blood pressure — tolazoline, phenoxybenzamine, terazosin and phentolamine — may also be beneficial for autism.
Drugs go through rigorous safety testing as part of their approval. This makes repurposing approved drugs an attractive alternative to developing new candidates.
In the new study, the researchers first created gene-interaction networks using candidate genes linked to each disorder. They found seven genes, including MTHFR, that are potential candidates for both autism and high blood pressure.
The researchers then explored whether any of these genes is a direct target of an existing drug. To account for drugs with unknown targets, they developed a ‘drug similarity’ network that links drugs based on their structure, side effects and known targets.
A drug for one disorder that has several similarities to a drug for a different disorder is considered to be a candidate treatment for the second disorder.
The researchers used this approach to look for connections between autism, high blood pressure, Crohn’s disease and diabetes.
The study suggests that risperidone — one of only two drugs approved to treat autism — may be beneficial for high blood pressure. It also found several connections between drugs for high blood pressure and those for diabetes.
1.Fukuoka Y. et al.Bioinformation 9, 89-93 (2013) PubMed
2. Lemonnier E. et al. Transl. Psychiatry 2, e202 (2012) PubMed